Not all of men with newly diagnosed prostate cancer need immediate treatment.

The Brady Urological Institute has achieved world renown for discoveries that led to improvements in the surgical treatment of prostate cancer. However, not every man will benefit from treatment since some cancers will never progress to a harmful state. Researchers at the Brady Urological Institute have a commitment to learn how to identify those men who can safely forego treatment -instead undergoing careful follow up for any evidence of progression of their disease (active surveillance). An active surveillance program at the Brady Urological Institute under the direction of  Dr. Christian Pavlovich has followed more than 1100 men over more than 15 years who are thought to have tumors that can be safely managed without immediate treatment.

The Johns Hopkins Active Surveillance Program is unique:

• Largest and longest ongoing surveillance study using strict criteria for recruitment developed at Johns Hopkins

• Close follow-up of men, with annual prostate biopsies performed using techniques that are based on original studies from Johns Hopkins

• Collection of blood and urine samples for future studies

• Multidisciplinary team of dedicated urologists, pathologists, radiologists, statisticians, basic scientists, and clinical coordinators working together to improve patient care through discovery

• Latest research findings translated into patient care before they become available to the medical community

 For more information about the Johns Hopkins Active Surveillance Program:

https://clinicalconnection.hopkinsmedicine.org/news/robust-innovative-forward-thinking-personalized-active-surveillance-safer-surgery